Griffin K. Hughes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Griffin K. Hughes has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Matt Vassar
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, USA
16 shared publications - Alyson Haslam
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, USA
7 shared publications - Andriana M. Peña
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, USA
7 shared publications - Ryan McIntire
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, USA
7 shared publications Matt Vassar
Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, OK, USA
6 shared publications- Vinay Prasad
Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, USA
6 shared publications
Latest Publications
- 6 February 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (3) , 66
Assessing patient risk, benefit, and outcomes in drug development: a decade of sorafenib clinical trials
- 6 February 2026
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 82 (3) , 66
Assessing patient risk, benefit, and outcomes in drug development: a decade of sorafenib clinical trials
- 23 January 2026
- Published by Springer Nature in Virchows Archiv
- Vol. 488 (2) , 291-299
Assessment of spin within diagnostic accuracy meta-analyses published in top pathology journals: a cross-sectional study
"Spin" - the overinterpretation of research findings - has been assessed in experimental and synthesis designs of interventional evidence. Little attention has been given to the assessment of spin in diagnostic evidence bases. Therefore, we conducted a cross-sectional study to assess for spin found within diagnostic accuracy meta-analyses published in top pathology journals. We searched PubMed for diagnostic test accuracy meta-analyses published in top 20 pathology journals from past to present. We applied published methodology to identify the presence of 10 items of actual overinterpretation and 9 items of potential overinterpretation. Authors screened and extracted relevant data from sample studies in a masked duplicate fashion to reduce extraction errors. On September 21st, 2023, we identified 207 articles from PubMed for potential inclusions. After screening, 55 abstracts and full-texts were available for full data extraction. with 80% (44/55) having positive conclusions germane to accuracy or clinical implications. Every meta-analysis contained one item of spin. Most positive conclusions in abstracts (75%; 33/44) and full-texts (79.6%; 35/44) did not adequately reflect pooled estimates while 19 (34.5%) studies employed non-recommended statistical approaches for pooling accuracy measures. Diagnostic test accuracy meta-analyses found within top pathology journals consistently overstate their conclusions. Authors should contextualize diagnostic summary effects within predetermined diagnostic performance. Further, authors should ensure that summary estimates are pooled using bivariate or hierarchical approaches that maintain threshold effects throughout meta-analytic calculations. Readers should cautiously interpret meta-analyses that fail to report sample sizes and confidence intervals of summary estimates.
- 23 January 2026
- Published by Springer Nature in Virchows Archiv
- Vol. 488 (2) , 291-299
Assessment of spin within diagnostic accuracy meta-analyses published in top pathology journals: a cross-sectional study
"Spin" - the overinterpretation of research findings - has been assessed in experimental and synthesis designs of interventional evidence. Little attention has been given to the assessment of spin in diagnostic evidence bases. Therefore, we conducted a cross-sectional study to assess for spin found within diagnostic accuracy meta-analyses published in top pathology journals. We searched PubMed for diagnostic test accuracy meta-analyses published in top 20 pathology journals from past to present. We applied published methodology to identify the presence of 10 items of actual overinterpretation and 9 items of potential overinterpretation. Authors screened and extracted relevant data from sample studies in a masked duplicate fashion to reduce extraction errors. On September 21st, 2023, we identified 207 articles from PubMed for potential inclusions. After screening, 55 abstracts and full-texts were available for full data extraction. with 80% (44/55) having positive conclusions germane to accuracy or clinical implications. Every meta-analysis contained one item of spin. Most positive conclusions in abstracts (75%; 33/44) and full-texts (79.6%; 35/44) did not adequately reflect pooled estimates while 19 (34.5%) studies employed non-recommended statistical approaches for pooling accuracy measures. Diagnostic test accuracy meta-analyses found within top pathology journals consistently overstate their conclusions. Authors should contextualize diagnostic summary effects within predetermined diagnostic performance. Further, authors should ensure that summary estimates are pooled using bivariate or hierarchical approaches that maintain threshold effects throughout meta-analytic calculations. Readers should cautiously interpret meta-analyses that fail to report sample sizes and confidence intervals of summary estimates.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Dabrafenib and trametinib (D&T) received accelerated approval by the FDA in 2022 for the treatment of metastatic solid tumors harboring BRAF mutations. Our aim was to evaluate the risk/benefit profile of D&T in clinical trials. A comprehensive literature search was conducted to identify relevant clinical trial publications involving D&T in adult malignancies. Trials utilizing D&T measuring responses with RECIST or other criteria were included. Data screening and extraction were performed in a masked, duplicate fashion, focusing on adverse events (AE) and primary endpoints. D&T were evaluated in many BRAFV600-mutated cancers. The median progression-free survival across all trials was 4.5 months and the median overall survival was 11.5 months. However, 34% of trials did not report or reach their progression-free survival endpoint, and 54% did not report or obtain an overall survival value. The cumulative objective response rate remained consistent at around 30% throughout drug development, but the cumulative incidence of grade 3 to 5 AEs increased from 25% to 50% as off-label indications were studied. We found the studies that led to the accelerated approval of D&T’s use in indications outside its original label to be deficient in reporting AEs and outcomes. The accelerated approval filled a space needed for the treatment of other BRAFV600 malignancies that did not have a standard method of treatment. However, it is still imperative that clinical trial data be empirically driven and transparent. This encourages quality research which lays the foundation for clinical decision making that affects patient quality of life and outcomes.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Dabrafenib and trametinib (D&T) received accelerated approval by the FDA in 2022 for the treatment of metastatic solid tumors harboring BRAF mutations. Our aim was to evaluate the risk/benefit profile of D&T in clinical trials. A comprehensive literature search was conducted to identify relevant clinical trial publications involving D&T in adult malignancies. Trials utilizing D&T measuring responses with RECIST or other criteria were included. Data screening and extraction were performed in a masked, duplicate fashion, focusing on adverse events (AE) and primary endpoints. D&T were evaluated in many BRAFV600-mutated cancers. The median progression-free survival across all trials was 4.5 months and the median overall survival was 11.5 months. However, 34% of trials did not report or reach their progression-free survival endpoint, and 54% did not report or obtain an overall survival value. The cumulative objective response rate remained consistent at around 30% throughout drug development, but the cumulative incidence of grade 3 to 5 AEs increased from 25% to 50% as off-label indications were studied. We found the studies that led to the accelerated approval of D&T’s use in indications outside its original label to be deficient in reporting AEs and outcomes. The accelerated approval filled a space needed for the treatment of other BRAFV600 malignancies that did not have a standard method of treatment. However, it is still imperative that clinical trial data be empirically driven and transparent. This encourages quality research which lays the foundation for clinical decision making that affects patient quality of life and outcomes.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Supplementary Table S1: Clinical Trial Publications With Multiple Indications
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Supplementary Table S1: Clinical Trial Publications With Multiple Indications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Supplementary Figure S1: Flow diagram for study inclusion.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Supplementary Figure S1: Flow diagram for study inclusion.
- 6 October 2025
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 164 (5) , 785-792
Assessing the process reproducibility of meta-analyses published in the top 20 pathology journals: A cross-sectional study
Objective: The objective of this study is to investigate the rigor of reporting and the potential for process reproducibility of meta-analyses published within top pathology journals. Methods: This cross-sectional, meta-research study assessed eligible systematic reviews with meta-analysis indexed in MEDLINE through PubMed. We included those studies that were published within the top 20 pathology journals (h-5 index) from inception to March 21, 2024. We extracted proper reporting variables across 4 key quantitative synthesis domains: (1) primary study eligibility, (2) search strategy, (3) screening and extraction methods, and (4) quantitative synthesis approach. Results: We found 282 studies eligible for masked duplicate data extraction. Less than half of studies (40.8% ± 2.9%) reported whether unpublished literature was eligible for inclusion, while less than 20% reported the date of their database search (18.8% ± 2.3%). Similarly, less than 20% reported a full, reproducible search strategy (19.1% ± 2.3%). Not all studies reported primary study effects (92.9% ± 1.5%). The reported use or mention of a relevant synthesis reporting guideline was associated with significant improvement in reporting of search factors (P < .001) and screening factors (P < .001). Nine meta-analyses (9 of 282; 3.2%) were deemed potentially process-reproducible. Conclusions: Fewer than 10 meta-analyses from top pathology journals were potentially process-reproducible without reasonable effort. Most individual summary estimates were reproducible due to the presence of forest plots. Nevertheless, reproducibility factors related to search strategies are the single largest hindrance to reproducible meta-analyses published within our sample.
- 6 October 2025
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 164 (5) , 785-792
Assessing the process reproducibility of meta-analyses published in the top 20 pathology journals: A cross-sectional study
Objective: The objective of this study is to investigate the rigor of reporting and the potential for process reproducibility of meta-analyses published within top pathology journals. Methods: This cross-sectional, meta-research study assessed eligible systematic reviews with meta-analysis indexed in MEDLINE through PubMed. We included those studies that were published within the top 20 pathology journals (h-5 index) from inception to March 21, 2024. We extracted proper reporting variables across 4 key quantitative synthesis domains: (1) primary study eligibility, (2) search strategy, (3) screening and extraction methods, and (4) quantitative synthesis approach. Results: We found 282 studies eligible for masked duplicate data extraction. Less than half of studies (40.8% ± 2.9%) reported whether unpublished literature was eligible for inclusion, while less than 20% reported the date of their database search (18.8% ± 2.3%). Similarly, less than 20% reported a full, reproducible search strategy (19.1% ± 2.3%). Not all studies reported primary study effects (92.9% ± 1.5%). The reported use or mention of a relevant synthesis reporting guideline was associated with significant improvement in reporting of search factors (P < .001) and screening factors (P < .001). Nine meta-analyses (9 of 282; 3.2%) were deemed potentially process-reproducible. Conclusions: Fewer than 10 meta-analyses from top pathology journals were potentially process-reproducible without reasonable effort. Most individual summary estimates were reproducible due to the presence of forest plots. Nevertheless, reproducibility factors related to search strategies are the single largest hindrance to reproducible meta-analyses published within our sample.
- 10 July 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (11) , 1701-1711
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Dabrafenib and trametinib (D&T) received accelerated approval by the FDA in 2022 for the treatment of metastatic solid tumors harboring BRAF mutations. Our aim was to evaluate the risk/benefit profile of D&T in clinical trials. A comprehensive literature search was conducted to identify relevant clinical trial publications involving D&T in adult malignancies. Trials utilizing D&T measuring responses with RECIST or other criteria were included. Data screening and extraction were performed in a masked, duplicate fashion, focusing on adverse events (AE) and primary endpoints. D&T were evaluated in many BRAFV600-mutated cancers. The median progression-free survival across all trials was 4.5 months and the median overall survival was 11.5 months. However, 34% of trials did not report or reach their progression-free survival endpoint, and 54% did not report or obtain an overall survival value. The cumulative objective response rate remained consistent at around 30% throughout drug development, but the cumulative incidence of grade 3 to 5 AEs increased from 25% to 50% as off-label indications were studied. We found the studies that led to the accelerated approval of D&T’s use in indications outside its original label to be deficient in reporting AEs and outcomes. The accelerated approval filled a space needed for the treatment of other BRAFV600 malignancies that did not have a standard method of treatment. However, it is still imperative that clinical trial data be empirically driven and transparent. This encourages quality research which lays the foundation for clinical decision making that affects patient quality of life and outcomes.
- 10 July 2025
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 24 (11) , 1701-1711
Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Dabrafenib and Trametinib Clinical Trials
Dabrafenib and trametinib (D&T) received accelerated approval by the FDA in 2022 for the treatment of metastatic solid tumors harboring BRAF mutations. Our aim was to evaluate the risk/benefit profile of D&T in clinical trials. A comprehensive literature search was conducted to identify relevant clinical trial publications involving D&T in adult malignancies. Trials utilizing D&T measuring responses with RECIST or other criteria were included. Data screening and extraction were performed in a masked, duplicate fashion, focusing on adverse events (AE) and primary endpoints. D&T were evaluated in many BRAFV600-mutated cancers. The median progression-free survival across all trials was 4.5 months and the median overall survival was 11.5 months. However, 34% of trials did not report or reach their progression-free survival endpoint, and 54% did not report or obtain an overall survival value. The cumulative objective response rate remained consistent at around 30% throughout drug development, but the cumulative incidence of grade 3 to 5 AEs increased from 25% to 50% as off-label indications were studied. We found the studies that led to the accelerated approval of D&T’s use in indications outside its original label to be deficient in reporting AEs and outcomes. The accelerated approval filled a space needed for the treatment of other BRAFV600 malignancies that did not have a standard method of treatment. However, it is still imperative that clinical trial data be empirically driven and transparent. This encourages quality research which lays the foundation for clinical decision making that affects patient quality of life and outcomes.
- Open Access
- 22 May 2025
- Published by Elsevier in JSES Reviews, Reports, and Techniques
- Vol. 5 (4) , 820-827
The usefulness of orthopedic shoulder surgery randomized controlled trials: are they meeting the key criteria?
- 22 May 2025
- Published by Elsevier in JSES Reviews, Reports, and Techniques
- Vol. 5 (4) , 820-827
Open AccessThe usefulness of orthopedic shoulder surgery randomized controlled trials: are they meeting the key criteria?
- 15 May 2025
- Published by BMJ in Journal of Clinical Pathology
- Vol. 79 (1) , 37-42
Improving transparency in publishing: gaps in standardised reporting across surgical pathology and laboratory medicine journals
Aims Research reporting checklists are itemised writing standards to improve transparency and facilitate reproducibility. Previous assessments of their recommendation or requirement have demonstrated improved checklist adherence across medical specialties and study designs. Here, we investigated the endorsement of reporting checklists within pathology, laboratory medicine and forensic science journals. Methods We queried Google Scholar Metrics and the Scopus CiteScore tool to identify top pathology and forensic medicine journals. Two authors independently assessed for the mention, recommendation or requirement or checklists—derived from the Enhancing the Quality and Transparency Of Health Research (EQUATOR) network—as well as study preregistration within each journal’s aims and instructions for authors. Journal editors were contacted by one author every 3 weeks to confirm whether or not certain study designs would be considered for publication. Results Of the 88 journals evaluated, most did not mention or endorse the EQUATOR Network (73.9%) or International Committee of Medical Journal Editors reporting standards (51.1%). The most commonly reported checklists included Animal Research: Reporting of In Vivo Experiments (38.6%), Consolidated Standards of Reporting Trials (28.4%) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (25.0%). The CARE reporting checklist for case reports was required most often by five journals (5.7%). The final email response from journal editors and contacts was 9.1%. Conclusions Reporting checklists were suboptimally mentioned and rarely required. Even with many basic and diagnostic science reporting checklists and initiatives, endorsement remains low. We recommend that authors, reviewers and editors become familiar with relevant reporting checklists for their fields and publishing spaces to improve checklist visibility and adherence for scientific transparency, reproducibility and rigour.
- 15 May 2025
- Published by BMJ in Journal of Clinical Pathology
- Vol. 79 (1) , 37-42
Improving transparency in publishing: gaps in standardised reporting across surgical pathology and laboratory medicine journals
Aims Research reporting checklists are itemised writing standards to improve transparency and facilitate reproducibility. Previous assessments of their recommendation or requirement have demonstrated improved checklist adherence across medical specialties and study designs. Here, we investigated the endorsement of reporting checklists within pathology, laboratory medicine and forensic science journals. Methods We queried Google Scholar Metrics and the Scopus CiteScore tool to identify top pathology and forensic medicine journals. Two authors independently assessed for the mention, recommendation or requirement or checklists—derived from the Enhancing the Quality and Transparency Of Health Research (EQUATOR) network—as well as study preregistration within each journal’s aims and instructions for authors. Journal editors were contacted by one author every 3 weeks to confirm whether or not certain study designs would be considered for publication. Results Of the 88 journals evaluated, most did not mention or endorse the EQUATOR Network (73.9%) or International Committee of Medical Journal Editors reporting standards (51.1%). The most commonly reported checklists included Animal Research: Reporting of In Vivo Experiments (38.6%), Consolidated Standards of Reporting Trials (28.4%) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (25.0%). The CARE reporting checklist for case reports was required most often by five journals (5.7%). The final email response from journal editors and contacts was 9.1%. Conclusions Reporting checklists were suboptimally mentioned and rarely required. Even with many basic and diagnostic science reporting checklists and initiatives, endorsement remains low. We recommend that authors, reviewers and editors become familiar with relevant reporting checklists for their fields and publishing spaces to improve checklist visibility and adherence for scientific transparency, reproducibility and rigour.
- 14 May 2025
- Published by Wiley in Tropical Medicine & International Health
- Vol. 30 (7) , 580-587
Endorsement of reporting guidelines and clinical trial registration by tropical medicine and infectious disease journals: A cross‐sectional study
Background: Studies published in academic medical journals inform and influence healthcare decisions. Sufficient study reporting is primarily charged to researchers. However, journals can promote more complete reporting of their published studies. Recommending or requiring reporting guideline use and prospective trial registration may ensure published studies adhere to rigorous reporting standards. This study aimed to evaluate ‘instructions to authors’ pages of tropical medicine and infectious disease (TM/ID) journals to assess endorsement of reporting guidelines (RGs) for common medical study designs and clinical trial registration.Methods: Using a cross‐sectional design guided by the Strengthening the Reporting of Observational Studies in Epidemiology checklist, we examined the top 100 infectious disease (ID) journals identified by the 2021 Scopus CiteScore tool and the 21 tropical medicine (TM) journals identified by Clarivate Web of Science. Each editorial journal staff was contacted for specific study designs accepted. Data were extracted from journals' ‘instructions to authors’ webpages with any discrepancies being resolved through consensus. We assessed adherence to RGs and clinical trial registration.Results: This study identified 293 TM/ID journals. Among the top 100 ID journals selected (Scopus CiteScore), 2 unfit journals were replaced. Among the 28 TM journals selected (Clarivate Web of Science), 5 were removed due to being duplicates and 2 were removed due to not being published in English. The Enhancing the QUAlity and Transparency Of health Research (EQUATOR) Network was cited by 49% of journals, while 85% of journals referenced the International Committee of Medical Journal Editors (ICMJE). Consolidated Standards of Reporting Trials (CONSORT) was most cited (73%), Quality of Reporting of Meta‐analyses was least (2.6%). Clinical trial registration was mentioned by 73% of the journals.Conclusions: TM and ID journals demonstrated suboptimal endorsement of various RGs. Among our findings, however, CONSORT and clinical trial registration garnered over 70% endorsement. We propose journals streamline RGs, establish user‐friendly ‘instructions to authors’ pages and mandate reporting guideline adherence. These insights inform future research on enhancing reporting guideline use and TM/ID research quality.
- 14 May 2025
- Published by Wiley in Tropical Medicine & International Health
- Vol. 30 (7) , 580-587
Endorsement of reporting guidelines and clinical trial registration by tropical medicine and infectious disease journals: A cross‐sectional study
Background: Studies published in academic medical journals inform and influence healthcare decisions. Sufficient study reporting is primarily charged to researchers. However, journals can promote more complete reporting of their published studies. Recommending or requiring reporting guideline use and prospective trial registration may ensure published studies adhere to rigorous reporting standards. This study aimed to evaluate ‘instructions to authors’ pages of tropical medicine and infectious disease (TM/ID) journals to assess endorsement of reporting guidelines (RGs) for common medical study designs and clinical trial registration.Methods: Using a cross‐sectional design guided by the Strengthening the Reporting of Observational Studies in Epidemiology checklist, we examined the top 100 infectious disease (ID) journals identified by the 2021 Scopus CiteScore tool and the 21 tropical medicine (TM) journals identified by Clarivate Web of Science. Each editorial journal staff was contacted for specific study designs accepted. Data were extracted from journals' ‘instructions to authors’ webpages with any discrepancies being resolved through consensus. We assessed adherence to RGs and clinical trial registration.Results: This study identified 293 TM/ID journals. Among the top 100 ID journals selected (Scopus CiteScore), 2 unfit journals were replaced. Among the 28 TM journals selected (Clarivate Web of Science), 5 were removed due to being duplicates and 2 were removed due to not being published in English. The Enhancing the QUAlity and Transparency Of health Research (EQUATOR) Network was cited by 49% of journals, while 85% of journals referenced the International Committee of Medical Journal Editors (ICMJE). Consolidated Standards of Reporting Trials (CONSORT) was most cited (73%), Quality of Reporting of Meta‐analyses was least (2.6%). Clinical trial registration was mentioned by 73% of the journals.Conclusions: TM and ID journals demonstrated suboptimal endorsement of various RGs. Among our findings, however, CONSORT and clinical trial registration garnered over 70% endorsement. We propose journals streamline RGs, establish user‐friendly ‘instructions to authors’ pages and mandate reporting guideline adherence. These insights inform future research on enhancing reporting guideline use and TM/ID research quality.